Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 252

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP 2C19 genotype

Kagami, T., Sahara, S., Ichikawa, H., Uotani, T., Yamade, M., Sugimoto, M., Hamaya, Y., Iwaizumi, M., Osawa, S., Sugimoto, K., Miyajima, H., Furuta, T.·2016·Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: Acid inhibitory effects of proton pump inhibitors (PPI s) are influenced by CYP 2C19 genotype. In contrast, the potent acid inhibition of vonoprazan is not influenced by CYP 2C19 genotype. Aim: To compare the acid inhibitory effects of vonoprazan and esomeprazole in relation to CYP 2C19 genotype. Methods: Twenty‐eight healthy Japanese volunteers [7 CYP 2C19 poor metabolisers (PM s), 11 intermediate metabolisers (IM s) and 10 rapid metabolisers (RM s)] received four different regimens in a randomised crossover manner: (i) vonoprazan 20 mg twice daily (b.d.), (ii) vonoprazan 20 mg daily, (iii) esomeprazole 20 mg b.d. and (iv) esomeprazole 20 mg daily. The timing of each dosing was 1 h before a meal. Twenty‐four‐hour intragastric pH monitoring was performed on day 7 on each regimen. Results: In the overall genotype group,pH≥4 holding time ratios (pH 4 HTR s) with vonoprazan b.d., vonoprazan daily, esomeprazole b.d. and esomeprazole daily were 100%, 95%, 91%, and 68% respectively.pH 5 HTR s were 99%, 91%, 84% and 54% respectively. Vonoprazan b.d. potently suppressed acid for 24 h, and was significantly superior to other regimens irrespective of CYP 2C19 genotype. Vonoprazan daily was equivalent to esomeprazole b.d. in IM s and PM s, but superior in RM s.CYP 2C19 genotype‐dependent differences were observed in esomeprazole daily but not in vonoprazan b.d. or daily. Conclusion: Vonoprazan 20 mg b.d. inhibits acid irrespective of CYP 2C19 genotype, more potently than esomeprazole 20 mg b.d.,pH 4 and 5 holding time ratios reached 100% and 99%, respectively.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.13588

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 252

Metadata

Authors
Kagami, T., Sahara, S., Ichikawa, H., Uotani, T., Yamade, M., Sugimoto, M., Hamaya, Y., Iwaizumi, M., Osawa, S., Sugimoto, K., Miyajima, H., & Furuta, T.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2016-03-18
Volume
43
Issue
10
Pages
1048-1059
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2301012193
Cited by
252
References
1
FWCI
25.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP 2C19 genotype. https://app.cochat.ai/papers/10.1111/apt.13588
The paper
Kagami, T., Sahara, S., Ichikawa, H., Uotani, T., Yamade, M., Sugimoto, M., Hamaya, Y., Iwaizumi, M., Osawa, S., Sugimoto, K., Miyajima, H., & Furuta, T. (2016). Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP 2C19 genotype. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.13588

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.